{"id":5069,"date":"2026-09-11T21:20:58","date_gmt":"2026-09-12T02:20:58","guid":{"rendered":"https:\/\/directsourcenews.org\/index.php\/2026\/09\/11\/biohaven-faces-new-securities-investigation\/"},"modified":"2026-09-11T21:21:01","modified_gmt":"2026-09-12T02:21:01","slug":"biohaven-faces-new-securities-investigation","status":"publish","type":"post","link":"https:\/\/directsourcenews.org\/index.php\/2026\/09\/11\/biohaven-faces-new-securities-investigation\/","title":{"rendered":"Biohaven Faces New Securities Investigation"},"content":{"rendered":"<p> NEW YORK \u2013 September 11, 2026 (STL.News) Biohaven Ltd. (NYSE: BHVN) is facing a new securities investigation after the biotechnology company\u2019s shares fell nearly 15% following disclosure that the U.S. Food and Drug Administration placed a partial clinical hold on new patient enrollment in trials involving its experimental epilepsy treatment BHV-7000, also known as opakalim. Levi &amp; Korsinsky LLP announced Friday that it is investigating potential federal securities law claims on behalf of Biohaven investors. The announcement comes one day after Biohaven shares fell $2.21, or about 14.73%, after the FDA action was disclosed. The latest development is particularly<\/p>\n<p><strong>Source:<\/strong> <a href=\"https:\/\/www.stl.news\/biohaven-faces-new-securities-investigation\/\" target=\"_blank\" rel=\"nofollow noopener\">Read Original Article<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK \u2013 September 11, 2026 (STL.News) Biohaven Ltd. (NYSE: BHVN) is facing a new securities investigation after the biotechnology company\u2019s shares fell nearly 15% following disclosure that the U.S. Food and Drug Administration placed a partial clinical hold on&#8230; <\/p>\n","protected":false},"author":1,"featured_media":5070,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-5069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/directsourcenews.org\/index.php\/wp-json\/wp\/v2\/posts\/5069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/directsourcenews.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/directsourcenews.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/directsourcenews.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/directsourcenews.org\/index.php\/wp-json\/wp\/v2\/comments?post=5069"}],"version-history":[{"count":1,"href":"https:\/\/directsourcenews.org\/index.php\/wp-json\/wp\/v2\/posts\/5069\/revisions"}],"predecessor-version":[{"id":5071,"href":"https:\/\/directsourcenews.org\/index.php\/wp-json\/wp\/v2\/posts\/5069\/revisions\/5071"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/directsourcenews.org\/index.php\/wp-json\/wp\/v2\/media\/5070"}],"wp:attachment":[{"href":"https:\/\/directsourcenews.org\/index.php\/wp-json\/wp\/v2\/media?parent=5069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/directsourcenews.org\/index.php\/wp-json\/wp\/v2\/categories?post=5069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/directsourcenews.org\/index.php\/wp-json\/wp\/v2\/tags?post=5069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}